On July 1, Tianxin Pharmaceutical’s new shares were subscribed online and offline at the same time. The subscription price was 36.88 yuan per share. The online subscription was referred to as “Tianxin Subscription”, and the subscription code was “732235”. The maximum subscription quantity for a single online securities account is 13,000 shares. Tianxin Pharmaceutical issued 43.78 million new shares this time, with a total share capital of 437.78 million shares after the issuance, and was listed on the Shanghai Stock Exchange.
Tianxin Pharmaceutical is committed to the R&D, production and sales of monomeric vitamins. Its products include vitamin B6, vitamin B1, biotin, folic acid, vitamin D3, ascorbyl palmitate, vitamin E powder, etc. With years of technical accumulation in the field of monomeric vitamins, good customer relationships, and excellent product quality, Tianxin Pharmaceutical’s series of products are widely recognized by customers and have a high reputation. Among them, the market share of vitamin B6 and vitamin B1 products leads the world. .
According to Tianxin Pharmaceutical, the raised funds will be invested in the “Project with an annual output of 1,000 tons of vitamin A”, “Project with an annual output of 7,000 tons of vitamin B5”, “Project with an annual output of 350 tons of cholesterol and 6 tons of 25-hydroxyvitamin D3”, “sales Network and Smart Factory Project”, “Enterprise Research Institute Project” and replenish working capital. The above-mentioned fundraising projects are all centered on the company’s main business and development strategy, and are used to build the company’s new product production line to improve product structure, expand production capacity, enhance the company’s R&D strength and product reserve, strengthen marketing network construction, and enhance market competitiveness and brand influence. force.
Xu Jiangnan, chairman of Tianxin Pharmaceutical, said at the road show a few days ago that Tianxin Pharmaceutical will adhere to the innovative spirit of “daily innovation, and daily innovation” in the future, give full play to the company’s advantages in production system, quality management, and customer resources, and deeply cultivate In the vitamin industry, we will make products more refined, better, and stronger, enrich product categories, and build a global vitamin production platform. At the same time, Tianxin Pharmaceutical will further deepen the cooperation between upstream and downstream of the industrial chain, strive for excellence in production, technology and quality, actively participate in international pharmaceutical and food industry certification, promote the high-end development strategy of Tianxin products, and enhance the influence of Tianxin brand. Continue to provide high value-added products and services for global customers. (Li Ping)